Radar Telegram alerts Open Radar

The Chinese supplier of biochemicals from the Promomed group found itself under FDA sanctions: the Russian plant's debt to it reached 844.3 million rubles.

תרגם לעברית

Компромат ГРУПП · · Source

🇺🇸 USA · Map

The Chinese supplier of biochemicals from the Promomed group found itself under FDA sanctions: the Russian plant's debt to it reached 844.3 million rubles.

At the end of 2025, the Saransk Biochemical plant, part of the Promomed group, had a debt to the Chinese company Chengdu Shengnuo Biopharm in the amount of 844.3 million rubles. This amount amounted to 41.7% of the total payments of the enterprise, which made the Chinese counterparty the largest creditor of the enterprise.

In September 2026, the US Food and Drug Administration (FDA) placed Chengdu Shangguan on a 66-40 import alert due to violations found at its manufacturing sites. The American market provided the company with 32.83% of revenues in the first half of 2026. After the restrictions came into effect, parent company Chengdu Shengnuo Biotec announced a temporary suspension of the supply of active peptide pharmaceutical ingredients (API) to the United States pending the resolution of the regulatory claims.

At the same time, the financial reports of the Fromamed group do not contain details about the range of supplies from Chengdu, which leaves open the question of whether materials from this Chinese manufacturer were used in the production of drugs in biochemical facilities.

More on Radar

Want to see every report in real time?

Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.

Sign up free
Share on WhatsApp Get alerts on Telegram